Mariana Romero Roy
Latin America’s healthcare systems are confronting a fundamental shift in the diseases they diagnose and treat. While infectious diseases and emerging health threats remain prevalent, the burden is increasingly tilting toward chronic, noncommunicable conditions—most notably cardiovascular disease and cancer. [1]
As hospitals prepare for more complex patients and more sophisticated interventions, capital investment is shifting toward equipment that enables earlier diagnosis, guides minimally invasive procedures, and delivers highly targeted therapies. Advanced imaging systems, cardiovascular intervention tools, radiotherapy equipment, and AI-enabled diagnostic platforms are rapidly becoming essential infrastructure for the modern regional hospital.
The Disease Burden Is Driving the Budget
The figures behind this epidemiological shift are staggering. The Pan American Health Organization (PAHO) reports that noncommunicable diseases accounted for 65% of all deaths in the Americas in 2021, with cardiovascular diseases causing approximately 2.16 million deaths and cancer claiming another 1.37 million lives. [2]
Cardiovascular disease remains the single largest cause of disease burden across the Americas, and rapid population aging will only increase the number of affected patients in the coming years. [3]
Cancer poses a similarly urgent challenge. Data from the International Agency for Research on Cancer’s GLOBOCAN shows a substantial cancer burden across Latin America and the Caribbean, driven primarily by breast, prostate, colorectal, and lung malignancies. [4] For hospital executives, these demographic trends carry direct capital implications: shifting patient populations inevitably establish new equipment demands.
A rise in cardiac patients fuels demand for catheterization labs, image-guided interventional suites, and advanced cardiovascular diagnostic tools. Likewise, expanding cancer cohorts drive the necessity for advanced imaging, pathology, radiation oncology, and treatment-planning infrastructure. Increasingly, healthcare institutions must integrate these capabilities under a single roof.
The Operating Room Gets an Upgrade
One of the clearest reflections of this trend is the modernization of existing operating rooms and interventional suites. Rather than building entirely new facilities, hospitals are maximizing their existing physical footprints by retrofitting rooms with real-time imaging systems that allow specialists to perform increasingly complex procedures.
Mobile C-arms play a critical role in this environment. By offering intraoperative fluoroscopy, these mobile systems support orthopedic, vascular, cardiac, and other image-guided procedures without requiring a dedicated fixed-imaging room. This procedural flexibility is invaluable for hospitals striving to boost throughput without constructing new surgical suites for every subspecialty.
The broader surgical market is moving in the same direction. GHI’s analysis of Latin America’s surgical market reveals that adoption of minimally invasive technologies—including endoscopy, laparoscopy, and robotic-assisted surgery—is outpacing the growth of the overall installed surgical base. [5]
The same operational rationale applies to image-guided cardiovascular interventions. Next-generation catheterization laboratories integrate high-resolution imaging with advanced software and workflow tools, empowering clinicians to visualize complex anatomy, navigate interventions, and evaluate results in real time. Because cardiovascular disease represents the region’s heaviest burden, these catheterization labs are no longer viewed as specialty luxuries but as core strategic infrastructure. [3]
Cath Labs Are Becoming More Than Imaging Rooms
The modern cath lab is undergoing a major functional evolution. Cardiologists increasingly rely on advanced image guidance to perform procedures that previously required invasive open surgery, including complex coronary interventions and structural heart procedures. As a result, cath lab technology directly impacts a hospital’s broader operational goals, such as shortening patient lengths of stay and expanding procedural capacity.
This trend aligns seamlessly with the broader shift toward minimally invasive care across Latin America. GHI estimates that the region’s surgical robotics market generated approximately $246.6 million in 2024 and is projected to reach $573.2 million by 2033, representing a 9.8% CAGR. [5]
Equipping a modern cath lab requires a comprehensive technological ecosystem: imaging equipment, hemodynamic monitoring, contrast-management systems, specialized surgical tables, ultrasound units, information systems, and specialized disposables. Similarly, state-of-the-art operating rooms combine C-arms, endoscopic equipment, surgical navigation, robotics, and integrated digital software.
Oncology Requires an Entire Technology Stack
Cancer care presents an even broader equipment footprint because treatment cannot rely on a single device. The clinical care continuum begins with early detection and diagnosis, moves through imaging and staging, and culminates in surgical intervention, radiation therapy, systemic treatment, or a combination of these modalities.
CT, MRI, mammography, and other advanced imaging modalities enable clinicians to detect abnormalities early, characterize lesions, and plan targeted treatment strategies. Earlier detection significantly broadens therapeutic options; as the World Health Organization emphasizes, early cancer diagnosis improves survival rates, lowers patient morbidity, and reduces overall care costs by catching disease before advanced progression. [6]
Artificial intelligence is rapidly integrating into this diagnostic framework. The FDA’s current database includes hundreds of authorized AI-enabled medical devices, with radiology technologies making up the majority, followed closely by cardiovascular applications. [7] For Latin American hospitals, AI-assisted imaging software helps radiologists triage urgent cases, flag abnormalities, and support interpretation—a crucial advantage in health systems with specialist shortages.
LINACs Signal a Deeper Oncology Investment
While diagnostic imaging is essential, it represents only one component of comprehensive cancer care. Radiotherapy capacity is equally vital. Linear accelerators (LINACs) serve as the foundation of modern external-beam radiation therapy, enabling precise, targeted tumor irradiation.
The International Atomic Energy Agency (IAEA) reported that 21 Latin American and Caribbean nations actively participated in its Rays of Hope initiative in 2024 to expand access to diagnostic imaging, nuclear medicine, and radiotherapy. The initiative provided direct procurement support for linear accelerators in countries including the Dominican Republic, Mexico, Uruguay, and Venezuela. [8]
The IAEA has long cited deficits in radiotherapy units, trained radiation oncologists, and qualified medical physicists as major structural challenges across Latin America and the Caribbean. Consequently, procuring a LINAC is rarely a simple aging equipment swap; it typically signals the creation or expansion of an entire oncology service line—requiring treatment planning, simulation, radiation oncology staffing, and quality assurance protocols.
The Real Competition Is for Capital
The common thread across oncology and cardiovascular care is that both require capital-intensive investments that compete for finite hospital resources. An institution allocating significant capital to a new LINAC, cath lab, or high-end imaging platform may have limited funds remaining for other departments. Conversely, a hospital with aging cardiovascular infrastructure may represent an immediate procurement opportunity compared to one that recently completed an oncology expansion.
This is precisely where targeted market intelligence proves invaluable. The question is no longer whether Latin America’s disease burden is shifting—the data confirms it. The actionable question for medical device manufacturers is which specific hospitals are responding to this shift and where they are allocating their capital.
Because hospital budgets are limited, a surge in capital allocation for oncology or cardiology technology naturally reduces spending in other areas. Winning in this market requires knowing exactly which clinical departments are securing capital.
What Comes Next?
Latin America’s MedTech sector is entering a phase where clinical demand and capital deployment are increasingly interconnected. The hospitals best positioned to thrive over the next decade must manage growing volumes of complex cardiovascular and cancer patients while improving diagnostic speed, procedural precision, and treatment throughput.
Achieving this requires retrofitting existing ORs, upgrading cath labs, expanding diagnostic imaging capacity, investing in radiation therapy infrastructure, and embedding AI into diagnostic workflows. It also means the next major equipment opportunity will not always be in a newly constructed hospital. Often, it lies within an established facility adapting to a changing patient population, replacing aging assets, and redirecting capital toward the chronic conditions that consume most clinical resources.
Stop guessing where capital equipment budgets are flowing. Contact GHI today. Leveraging our proprietary HospiScope database, we can show your sales teams precisely which hospitals are expanding their oncology services and which facilities operate aging cardiovascular equipment ready for replacement. The competitive advantage belongs to MedTech leaders who identify where the next capital investment will occur before the public tender is announced.
************
Sources:
https://www.paho.org/en/news/28-6-2024-new-paho-report-shows-ncds-continue-main-cause-death-and-disability-americas-warns
https://www.paho.org/en/news/2-7-2025-noncommunicable-disease-deaths-americas-have-risen-43-2000-paho-report-shows
https://www.paho.org/en/enlace/cardiovascular-disease-burden
https://gco.iarc.who.int/today/en
https://globalhealthintelligence.com/ghi-analysis/latin-americas-surgical-future-where-hospitals-are-investing-next/
https://www.who.int/publications/i/item/guide-to-cancer-early-diagnosis
https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-enabled-medical-devices
https://www.iaea.org/sites/default/files/gc/gc69-inf6.pdf
https://www.iaea.org/sites/default/files/16/11/detecting-and-treating-cervical0cancer-using-diagnostic-imaging-techniques-and-radiotherapy.pdf
